



Bioma's portable patient simulator for testing and servicing cardiac and respiration monitors.

Current Export Markets

U.S.A., Europe, Asia, Latin America, Caribbean

Company Summary

In 1984, Bioma Research Inc. was founded to produce high quality biomedical electronic instruments. Starting with a range of physiological simulators, the company currently offers five different models as well as the Multitester, a unique instrument designed specifically to assist cardiologists in preparing patients for Holter tests. Bioma's most recent development is in the field of electrocardiograph (ECG) monitoring equipment. The company plans to expand its existing product line to include more varied diagnostic test equipment.

Biomedical Instrumentation Inc.

110 Riviera Drive, Unit 7
Markham, Ontario
Canada L3R 5M1

Tel: (416) 475-3313
Fax: (416) 470-8505

Contact: H. Wodlinger
Vice-President

Products/Services

Computerized electrophysiology data acquisition system

Current Export Markets

U.S.A.

Company Summary

Established in 1982, Biomedical Instrumentation Inc. specializes in the design and manufacture of computerized diagnostic equipment for electrophysiology applications. In 1988, the company

introduced EPlab, a computerized data acquisition, storage and analysis system for the electrophysiology laboratory. The device connects to existing biological amplifiers and cardiac stimulators. Digitized signals are stored continuously on an optical disk as well as displayed on a monitor, and analysed. The reporting and analysing aspects of the system can be customized to suit individual requirements.

Biomira Inc.

9411-20 Avenue
Edmonton Research & Development Park
Edmonton, Alberta
Canada T6N 1E5

Tel: (403) 450-3761
Fax: (403) 463-0871

Contact: Gordon Politeski
President

Products/Services

Radioimmunoassays for quantitation of cancer-associated antigens

Current Export Markets

U.S.A., Europe, Latin America, Caribbean, Japan

Company Summary

Biomira Inc. is a leading Canadian biotechnology company involved in researching and developing, manufacturing and marketing products used for the diagnosis and treatment of cancer. Founded in 1985, Biomira's scientists have produced synthetic antigens and highly specific monoclonal antibodies for development of products used both in vitro and in vivo. Currently, the company markets four radioimmunoassay kits for the quantitation of antigens in breast, ovarian, and pancreatic cancers and gastrointestinal tumors. Two more are expected in 1989. Additionally, clinical trials are being conducted on radioimmunoimaging agents; trials with a new cancer vaccine will begin soon.



Biomira's Truquant line of diagnostic test kits are comprised of radioimmunoassays for the quantitative determination of antigens associated with various types of cancers.